An in vitro RNA synthesis system was established in which the influenza virus virion (minus-sense) RNA was made from the synthetic plus-sense RNA (cRNA) template by the purified viral polymerase complex. The cRNA promoter was studied by mutational analysis using the in vitro system, and on the basis of these experiments, the first 11 nucleotides of the 3' noncoding sequence were found to contain the minimum promoter required for virion RNA synthesis. The addition of extra nucleotides at the 3' end decreased the promoter activity of the templates, indicating that the viral polymerase does not recognize an internal promoter efficiently. The wild-type and mutated RNA templates were also tested in vivo by using the ribonucleoprotein transfection system. In contrast to the in vitro system, it was found that the majority of mutations at the 3'-terminal sequence significantly decreased or abolished chloramphenicol acetyltransferase (CAT) expression. These results suggest that the cRNA promoter overlaps other essential cis elements required for chloramphenicol acetyltransferase expression in vivo.
Influenza A virus is an enveloped virus that contains a segmented RNA genome (15) of negative polarity. The negative-sense virion RNAs (vRNAs) are templates for viral mRNA synthesis which is primed by 5' capped fragments derived from host-cell mRNAs. The viral mRNAs terminate at a stretch of U residues 17 to 22 nucleotides away from the 5' end of the vRNAs. Replication of vRNAs involves synthesis of full-length cRNAs, which in turn are the templates for synthesis of vRNA molecules. Thus, there are three types of virus-specific RNAs, i.e., vRNA, cRNA, and mRNA. Their synthesis takes place in the nucleus of infected cells and is dependent on the presence of the viral polymerase and the viral nucleoprotein (NP) (7) (8) (9) 22) .
Sequence analysis indicated that the coding region of each RNA segment of the influenza virus genome is flanked by noncoding sequences at both the 3' and 5' ends (2, 19, 23) . The first 12 nucleotides at the 3' terminus and the first 13 nucleotides at the 5' terminus are highly conserved among the eight RNA segments. The second feature is that the 3' and 5' noncoding sequences show partial inverted complementarity. It was postulated (2, 23) and later confirmed that vRNAs form panhandle structures in vivo (6) . It was also suggested that the noncoding sequences and the panhandle structure might serve as regulatory elements for influenza virus RNA transcription and replication and possibly also for the packaging of vRNAs into virions (2, 6) .
It has recently become possible to study the functions of these cis-acting elements. We developed a ribonucleoprotein (RNP) transfection system in which a recombinant RNA (CAT1 RNA) molecule containing the chloramphenicol acetyltransferase (CAT) gene in the negative sense and influenza virus RNA-specific noncoding sequences was transfected into Madin-Darby bovine kidney (MDBK) cells.
Following infection with influenza A/WSN/33 virus, CAT activity was detected in the RNP-transfected cells (12) . In addition, the recombinant RNA was packaged into virus particles. These results demonstrated that the 3' and 5' noncoding sequences are sufficient to provide the signals for * Corresponding author.
RNA transcription, RNA replication, and packaging of RNA into influenza virus particles (12) . A similar in vivo RNP transfection system has also recently been reported, and it was confirmed that regions of the 3' end of vRNAs act in cis to promote transcription (24) . We then proceeded to further investigate the signals for mRNA polyadenylation using our in vivo RNP transfection system (11) . In this study, a series of mutants was made with changes in the 3' and 5' noncoding regions of CAT1 RNA. It was found that the stretch of uridine residues and the panhandle structure of vRNAs, which is formed by the 3' and 5' termini, are essential for polyadenylation of viral mRNAs (11) .
Previously, an in vitro influenza virus RNA transcription system which utilizes purified influenza virus polymerase complexes had also been established (16) . Short RNA molecules containing, at their ends, sequences corresponding to the 3'-and 5'-terminal nucleotides of the influenza virus A/PR8/34 NS gene were transcribed. It was shown that the promoters for cRNA and vRNA synthesis lay within the 3' noncoding sequence of the respective templates (16, 17) . Recently, a similar in vitro approach using micrococcal nuclease-treated viral cores and synthetic cRNA or vRNA templates has also been reported (21) .
In the present paper, we expand on such in vitro studies and attempt to precisely define the promoter required for influenza virus vRNA synthesis. Conditions were established to quantitatively measure the synthesis of vRNA in vitro by using purified viral polymerase and synthetic cRNAs as the template. A complete set of mutants with substitutions in the first 13 nucleotides of the 3' noncoding sequence of cRNA was made, and the effects of substitution mutations on vRNA synthesis were assayed. Our results indicate that the first 11 nucleotides at the 3' end represent the minimum promoter for vRNA synthesis. An additional feature of this promoter is that it must be located at the very 3' end of the cRNA because the viral polymerase did not efficiently recognize these sequences when they were followed by extra nucleotides at the 3' end. The RNP transfection system was used to evaluate the same mutants in vivo.
show no loss of promoter activity in vitro have diminished CAT expression in vivo, the cRNA promoter sequence most likely overlaps other essential cis elements involved in viral gene expression. (4, 16) . Briefly, 10 mg of influenza A/PR8/34 virus was purified by sucrose cushion centrifugation, and the cells were disrupted in 2 ml of disruption buffer containing 1.5% Triton N-101 and 10 mg of lysolecithin at 31°C for 25 min. The disrupted virus was fractionated by centrifugation on a 30 to 70% glycerol (wt/vol) step gradient. Fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and proteins were identified by silver staining. The fractions containing the RNP were pooled and were then subjected to CsClglycerol gradient centrifugation. Polymerase fractions were again identified by SDS-PAGE and silver staining. Polymerase fractions containing the NP and three polymerase proteins were collected. These fractions were pooled and dialyzed first against 50 mM Tris-HCl (pH 7.5)-100 mM NaCI-10 mM MgCl-1 mM dithiothreitol-10% glycerol for 3 h at 4°C. Subsequently, the dialysis was continued for another 3 h against the same solution containing 50% glycerol.
Construction of plasmids. Plasmid pIVACAT200 was generated by the polymerase chain reaction with the following primers: 5'-GATTACGCCAAGCTTCTCGAGTAATACGA CTCAC-3' and 5'-GGGATCCTCTAGACGCCCTGCAGTA GAAACAAGGGTGTTTTTTGATCATTACGCCCCGCC-3' (Applied Biosystems, Inc.) and pIVACAT9 (7) as the template (12) . One insertion (G [underlined] ) and one mutation (T to C [underlined] ) were included in the latter primer, which led to the generation of a new BclI site (Fig. 1) . The polymerase chain reaction product was digested by restriction enzymes XbaI and HindlIl and inserted into the appropriate sites of pUC19 (Fig. 1) . Thus, the plasmid pIVA-CAT200 contains the sequences which would direct transcription of a plus-sense RNA (CAT200 RNA). The Bcll site was introduced to facilitate the construction of the mutant plasmids. The short, complementary oligonucleotides containing the 3' noncoding sequences with a singlesubstitution mutation were synthesized by using a DNA synthesizer (Applied Biosystems, Inc.) and were phosphorylated and annealed. Either P*tl and BclI or XbaI and BclI overhangs were formed upon annealing of the two oligonucleotides. Meanwhile, the pIVACAT200 was digested with either PstI and BclI or XbaI and BclI, and the larger DNA fragments were isolated by using a GeneClean kit (Bio 101, Inc.). The annealed oligonucleotides and the purified DNA fragments were ligated and transformed into competent GM161 cells (Fig. 1) . The presence of substitutions in the plasmids was confirmed by DNA sequencing. A similar strategy was used to obtain constructs which resulted in RNAs with an extra G, an extra GCGAG, or a deletion of the first five nucleotides at the 3' terminus. The RNAs with 13 extra nucleotides and with a deletion of the first nucleotide at the 3' end were obtained by T7 RNA polymerase transcription from pIVACAT200 digested with XbaI and PstI, respectively. In the latter case, DNA digested with PstI was rendered blunt with T4 DNA polymerase (20 Influenza virus polymerase reaction. The in vitro RNA synthesis was performed by using conditions described previously (16) . Briefly, in a total volume of 25 ,ul, about 0.5 ,ug of protein (three polymerase proteins and NP) was mixed with 1 ,ug Viral polymerase products labeled with [ca-32P]UTP were analyzed by 4% denaturing PAGE. Gels were exposed to X-ray films, and the appropriate bands were cut out from the gels. SOLVABLE (Du Pont-NEN, Inc.) was used to elute RNA from the gel slices. The counts of 3H and 32p were measured in the corresponding channels in a Beckman LS 5000TD counter, and corrections for spillover were made. The ratio of the radioactivity of 32P and 3H (in counts per minute) was established and used to measure template activity of synthetic mutant RNAs. The CAT200 RNA was included in every experiment to serve as the control.
RNase T, digestion. The reaction products of viral polymerase were analyzed by 4% PAGE. The wet gel was exposed to an X-ray film, and the appropriate gel slices were excised. The gel slices were crushed in 300 p.l of elution buffer (provided in the ribonuclease protection assay kit by Ambion, Inc.) and incubated at 37°C overnight. The gel pieces were pelleted, and the supernatant was collected. RNA was precipitated by adding ethanol in the presence of 10 p.g of tRNA as the carrier. The RNA pellet was resuspended in The mixtures were incubated at 37°C for 2 h. RESULTS Constructs. The design of pIVACAT200 is shown in Fig. 1 . The plasmid contains the truncated T7 RNA polymerase promoter, the 26 nucleotides of the 5' noncoding sequence, and the 22 nucleotides of the 3' noncoding sequence of the plus-sense copy of the NS gene of the influenza A/PR8/34 virus (as indicated in the corresponding boxes). The CATcoding sequence in the plus sense is inserted between the 5' and 3' noncoding sequences. The plasmid contains convenient restriction enzyme sites which allow mutagenesis of the 3' noncoding region (see Materials and Methods; Fig. 1 ). The CAT200 RNA and mutated RNA derivatives result from T7 RNA polymerase transcription of HgaI-digested plasmid DNAs (Fig. 1) .
In vitro vRNA synthesis by viral polymerase complex. The CAT200 RNA contains the coding sequence of the CAT gene and is comparable in size (713 nucleotides) to the smallest influenza virus gene (890 nucleotides). When CAT200 RNA was mixed with the purified viral polymerase complex in the presence of dinucleotide ApG, a product which comigrated with the CATI RNA marker transcribed from pIVACAT1 was obtained (12) (Fig. 2A, lane 3) . In addition to the template-specific product, a general background of bands ( Fig. 2A ) is seen; most likely, this background corresponds to products transcribed from truncated viral genomic RNA and defective interfering (DI) RNA not removed from RNP complexes during the CsCl-glycerol centrifugation step, since they are also present in lane 1 of Fig. 2A , in which no synthetic RNA template was added. Under the same condition, the vRNA synthesis activity of the viral polymerase complex was 20% of the cRNA synthesis activity, with CAT1 RNA as the template (Fig. 2A, lane 4) . It should also be noted that the reaction is absolutely dependent on the presence of ApG (Fig. 2A, lane 2) , which is a unique feature of the influenza virus-associated polymerase (16, 18) . The vRNA synthesis increases linearly for up to 2 h (Fig. 2B) . We also determined the linearity of the vRNA synthesis with respect to the concentration of RNA template added. In the range from 0.5 to 2 p.g of RNA template used, the amount of product of the viral polymerase reaction was proportional to that of the RNA template (Fig. 2C) . In order to determine whether the plus-sense RNA template is completely copied, a short RNA template was used so that a minor difference in size between template and product could be detected. The plasmid pM-wt was digested with MboII (16) and rendered blunt by T4 DNA polymerase (20) . A 53-nucleotide RNA resulted from the T7 RNA (E) The products of the viral polymerase reactions were analyzed on denaturing polyacrylamide gels, eluted from the gels, and subjected to RNase T1 digestion. Lanes 3 and 4 show the RNase T1 digestion patterns of viral polymerase products by using CAT200/3C RNA and CAT200 RNA, respectively, as the templates. The CAT200/3C RNA contains an A-to-C mutation in the third position of the 3' noncoding sequence. The RNase T1 digestion patterns of CAT1 RNA and CAT200 RNA transcribed from pIVACAT1 and pIVACAT200 by T7 RNA polymerase are shown for comparison in lanes 1 and 2, respectively. polymerase transcription and contained the 5' and 3' noncoding sequences derived from the plus-sense RNA of the influenza A/PR8/34 virus NS gene (16) . This RNA molecule was then used as template in an in vitro viral polymerase reaction. As shown in Fig. 2D , the product of the viral polymerase reaction (lane 3) comigrates with the marker prepared by T7 RNA polymerase transcription on a sequencing gel. This result suggests that vRNA synthesis primed by ApG starts at the third nucleotide of the template and terminates at the very 5' end of the template.
An RNase T1 digestion of the in vitro products was also performed in order to confirm that the viral polymerase products were vRNA molecules. The products of the viral polymerase reaction using CAT200 RNA and CAT200/3C RNA molecules were isolated on a 4% polyacrylamide gel, eluted from gel slices, and then digested with RNase T1. The digestion products were analyzed by electrophoresis, and the patterns of RNase T1 digestion (Fig. 2E, lanes 3 and 4) were compared with those generated by RNase T1 digestion of labeled CAT1 and CAT200 RNA molecules (Fig. 2E,   lanes 1 and 2) . The CAT200/3C RNA containing an A-to-C mutation in the third position of the 3' noncoding sequence was used because of its high template activity (see below). The RNase T1 digestion patterns of the in vitro reaction products were essentially identical to that of CAT1 RNA (minus sense) and were different from the digestion pattern of CAT200 RNA (positive sense). The predicted lengths of the large T1 oligonucleotides of CAT1 RNA and CAT200 RNA are 28 and 21 and 18 and 15 nucleotides, respectively, in accordance with the patterns seen in Fig. 2E . The results clearly show that the viral polymerase complex copied the CAT200 and CAT200/3C RNA templates to generate minussense RNAs.
Mutational analysis of the promoter sequence required for vRNA (minus-sense RNA) synthesis. In order to identify precisely those elements important in promoter function, a set of mutated RNA molecules which contained singlenucleotide substitutions within the 3'-terminal sequence was made. The template activity of each mutated RNA was determined in independent experiments. Two or more ex- GAC GAU GUC GAC GAU GAC GAC GAC AUC GAC GAC GAU GAU 1U 2C 3A 4U 5C 6U 7U 8U 9G 1OU 11U 12C 13C  FIG. 3 . Mutational analysis of the promoter sequence required for vRNA synthesis in vitro. The wild-type nucleotide sequence of the 3-terminal 13 nucleotides of CAT200 RNA is indicated (from left to right). The three substitution mutations of each position are shown above each nucleotide. All RNA templates containing a single-point mutation were examined by using the reaction conditions described in Materials and Methods. The CAT200 RNA was used as the control in each experiment. The vRNA synthesis activity of mutated RNA templates is represented as relative activity compared with that of the wild-type template (100%). The relative activity is the mean value of two or more separate experiments using RNA templates which were synthesized independently by T7 RNA polymerase transcription. Error bars were calculated as the standard deviations of two or more samples in independent experiments. periments were used to calculate the promoter activity of each mutated RNA. In each experiment, the template was 3H labeled and the product was 32p labeled to facilitate easy quantitation of the promoter activity of each mutant template. In addition, each separate experiment contained a CAT200 RNA control. The results of the mutational analysis are shown in Fig. 3 . Substitution mutations in positions 12 and 13 showed little effect on template activity. However, mutations in the 11th nucleotide position reduced the template activity. We thus conclude that the 11 3'-terminal nucleotides of cRNA represent the minimum promoter sequence required for vRNA synthesis as determined in this system. The substitution mutations in the first 11 nucleotides could be divided into three groups according to the effect on vRNA synthesis. Group one consists of mutations in positions 5, 8, 9, and 11. The common feature of these positions was that they showed little flexibility for mutations. Substitutions in these positions decreased vRNA synthesis in vitro. Therefore, these positions appear essential for recognition by the viral polymerase complex. Positions 3, 4, and 6 belong to a second group. Some substitutions in these positions resulted in an increase of template activity. Of particular note were substitutions 3A to 3C (3.4 fold), 4U to 4C (2.6 fold), and 6U to 6G (3.1 fold) which led to a substantial increase in template activity. A last group includes positions 2 U-to-G, U-to-A, or U-to-C mutation, respectively, in the first position. The vRNA synthesis activity is presented relative to that of the reaction in which CAT200 RNA was used as the template and ApG was used as the primer. Error bars were calculated as the standard deviation of two or more independent experiments.
were made to determine their effects on promoter activity (see below).
Priming activity of dinucleotides in vRNA synthesis in vitro. It has been speculated that dinucleotide primers had to be complementary to the 3' terminus of vRNA templates to be functional (18) . The main evidence for this assumption was that ApG, the most active primer, is complementary to the first two nucleotides (UC) of vRNA (5, 18) . However, in our study, the promoter activity of RNA templates containing mutations at the second position of the 3' terminus of cRNA was not changed in the presence of the ApG primer (Fig. 3) . To further investigate this question, we tested three other available dinucleotides, CpG, ApA and ApU, in the in vitro vRNA synthesis system using RNA templates which contained mutations at the first two positions. The results are shown in Fig. 4 . CpG efficiently primed the vRNA synthesis when CAT200/1G was used as the template in which the first nucleotide U was mutated to G. In this case, CpG became complementary to the first two nucleotides (GC) of the 3' terminus. When RNA molecules CAT200/1A and CAT200/1C were used as the template, viral polymerase was not efficiently primed by CpG. These results indicate that in the case of vRNA synthesis, the priming activity of dinucleotides is helped by complementarity at the first nucleotide position. However, the decreased transcription of mutants in position 1 (Fig. 3) is dependent on the presence of ApG as the primer and might be artifactual if a different primer is used by the virus in vivo. The data also suggest that the G in the second position of ApG is important since ApA and ApU both possess only a low priming activity for the wild-type RNA (see Fig. 4 ). It should also be noted that ApA and ApU did not show an increase in primer activity when the complementary templates CAT200/2U and CAT200/2A, respectively, were used (data not shown).
The majority of mutations at the 3' noncoding sequence of the plus-sense RNA abolish CAT expression. The RNP transfection system has been used to elucidate cis elements of the incubation, the cells were harvested and disrupted. The CAT activity of the cell extracts was detected. In some cases, the cell extracts were diluted with 0.25 M Tris-HCl, pH 7.5, to obtain CAT assays in the linear range. The CAT expression is presented relative to that produced by transfection of the CAT200 RNA (100%). Error bars were calculated as the standard deviation of two or more independent experiments. influenza virus genome (11, 12, 24) . The model RNAs used in most previous studies were negative-sense RNA molecules similar to the genomic RNA of influenza virus (11, 12) . But it was also shown that the plus-sense RNA molecule CAT9 could be replicated in cells containing viral proteins provided by vaccinia virus vectors (7) . We first tested whether CAT200 RNA could be amplified to the same level as CAT9 RNA following transfection into MDBK cells. A new efficient transfection protocol was employed (4), in which CAT200 RNA and CAT9 RNA were transcribed by T7 RNA polymerase in the presence of viral polymerase complex and were transfected into MDBK cells infected with WSN helper virus. At 14 to 16 h after transfection, cells were harvested. The same level of CAT activity was detected (data not shown) from the cell extracts derived from these two transfections. Usually, 100 ,ul of cell extract was harvested from each transfection, and 50 ,ul of 1:100-diluted cell extract generated a 15 to 30% conversion of chloramphenicol. Under the same condition, CAT activity detected from CAT1 RNA transfections was about two times higher than that of CAT200 transfections (data not shown).
All RNA molecules which contained single-substitution mutations in the first 13 nucleotides of the 3' noncoding sequence of cRNA were examined by using this system along with CAT200 RNA as the positive control. The CAT expression of the mutant RNAs was normalized against that of the CAT200 RNA. The results are shown in Fig. 5 . Mutations at positions 3, 4, 5, 8, and 9 abolished CAT expression completely, and two of the three mutations at positions 2, 7, 12, and 13 led to a loss of measurable CAT expression. The third mutation in these positions significantly decreased CAT expression. CAT expression was, however, detected for all RNAs with mutations in positions 1, 6, and 10. This dramatic decrease and loss of CAT Analysis of the effect of additions and deletions of nucleotides at the 3' noncoding sequence on vRNA synthesis and CAT expression. RNAs with an extra G, an extra GCGAG, or 13 extra nucleotides and a deletion of one or five nucleotides at the 3' terminus were tested for promoter activity. The results are shown in Fig. 6 . When the length is increased by an additional nucleotide at the 3' terminus of the cRNA, the promoter activity of the RNA templates decreases rapidly. Deletion of the first nucleotide or the first five nucleotides also decreases the template activity. These results indicate that the promoter required for vRNA synthesis is located in the 3' terminus of the cRNA segment and that the viral polymerase complex cannot efficiently recognize an internal promoter. All mutant RNAs were also tested in the RNP transfection system. Although the results confirm the observations made in vitro, the level of activity in vivo was consistently lower than that in vitro.
DISCUSSION
We have described conditions under which vRNA molecules were copied in vitro from synthetic cRNA templates by purified viral polymerase. The reaction was shown to be sequence specific and to be dependent on the presence of ApG as the primer. This system enabled us to analyze the promoter sequence required for vRNA synthesis. A series of mutants which contained single-nucleotide substitutions at the first 13 nucleotides of the 3' noncoding sequence of the cRNA was made, and these mutants were investigated by using the in vitro vRNA synthesis system. Only the first 11 nucleotides of the 3' noncoding sequence of the cRNA were found to contain the minimum promoter required for vRNA synthesis. This finding is partially supported by the evidence from in vivo studies using RNP transfection of CAT18 RNA, which contains a mutation in position 13 and is amplified to the same level as that of the wild-type RNA in vivo (11) . Although position 13 (11) . In addition, it is possible that the viral polymerase complex prepared from virus particles is different from the viral replicase in infected cells (22) . For example, the polymerase complex used in this study and an earlier study (21) can be primed for vRNA synthesis by a globin mRNA primer (data not shown), but this mechanism is most likely not the one by which vRNA synthesis is primed in vivo. In fact, Shapiro and Krug (22) have shown that an in vitro replication system using nuclear extracts from infected cells is independent of any primers. However, this system did not allow the study of synthetic RNA templates. Work is now in progress to isolate the viral replicase (free of endogenous cRNA) from virus-infected cells, to characterize it, and to compare it with that obtained from purified virus.
The addition of extra nucleotides at the 3' noncoding sequence decreases the promoter activity of cRNA templates in vitro as well as CAT expression in vivo. The template activity of these RNA molecules in vitro decreased with the number of extra nucleotides at the 3' end. When the RNA molecule with one extra nucleotide was transfected into virus-infected cells, the CAT activity was less than 20% of that of the wild-type RNA. The addition of five extra nucleotides at the 3' end of the RNA abolished CAT expression. These results indicate that the viral polymerase complex cannot efficiently recognize an internal promoter and that a free 3' end is important for the promoter in vivo. Deletion of one or five nucleotides also markedly affected template activity in vitro and CAT expression in vivo (Fig.  6) . These results confirm that the promoter required for vRNA synthesis is located at the 3' terminus of the 3' noncoding sequence of cRNAs. A similar pattern had been observed earlier for the interaction between the vRNA promoter and the viral polymerase complex in vitro and in vivo. Parvin et al. (16) showed that an RNA template with five extra nucleotides at the 3' noncoding sequence of the vRNA promoter was recognized and copied at approximately one-third the efficiency of the wild-type template, and the addition of 13 or 38 cxtra nucleotides at the 3' end abolished the template activity. Recently, Collins et al. reported that the addition of 11 heterogeneous nucleotides at the 3' terminus of an analog of the respiratory syncytial virus genomic RNA abolished CAT expression in a similar transfection system (1). Our results are, however, different from those obtained with the respiratory syncytial virus system, in which deletion of the first three nucleotides at the 3' end did not affect CAT expression in a similar in vivo replication system (1) .
The study of viral promoters may have important practical implications in light of recent developments to rescue transfectant viruses (3, 4. 10, 14) . Influenza virus RNA segments transcribed from plasmids were introduced into virus particles, and infectious viruses (transfectants) were obtained. Some of these transfectants have novel biological properties. For cxample, a chimeric neuraminidase gene which contained the coding region of the influenza virus A/WSN neuraminidase and the 3' and 5' noncoding sequences of the NS gene of the influenza B/Lee virus was introduced into the genome of the influenza A/WSN virus (14) . The rescued chimeric virus was attenuated in mice, was highly immunogenic, and protected mice against challenge virus. The results demonstrated that a change in the 3' and 5' noncoding sequences of the influenza virus RNA segment can alter expression of the gene and thus confers new characteristics to the rescued virus. The detailed analysis of regulatory cis elements will enhance our ability to control expression of the introduced genes as well as further our understanding of how influenza viruses replicate. On 
